<DOC>
	<DOCNO>NCT01346319</DOCNO>
	<brief_summary>Phase 1 Dose Escalating Study safety , tolerability pharmacokinetics testosterone hypogonadal male .</brief_summary>
	<brief_title>Study Safety , Tolerability Pharmacokinetics Testosterone Undecanoate Hypogonadal Males .</brief_title>
	<detailed_description>M12-778 rise multiple dose , randomize , double blind , placebo control single center study . It 5 dose group 20 subject dose group 1,2 3 24 subject dose group 4 5 ; total 84 subject . There 7 day period dose group 1,2 3 ass safety increase next dose . Dose group 4 5 run parallel . Subjects confine center 20 day dose group 1,2 3 33 day dose group 4 5 .</detailed_description>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria 1 . Serum total testosterone &lt; 300 ng/dL base two blood sample obtain 6 10 AM two separate occasion least 48 hour apart . Previously document total testosterone result obtain within 6 week Study Day 2 may use screen subject currently androgen replacement therapy , follow washout androgen replacement therapy . 2 . Subjects na√Øve androgen replacement washout 12 week follow intramuscular androgen injection ; 4 week follow topical buccal androgen ; 3 week follow oral androgen . Washout complete Study Day 2 . 3 . Subject judge good general health determine principal investigator base upon result medical history , physical examination , vital sign , laboratory profile 12 lead electrocardiogram ( ECG ) perform Screening . 4 . Must voluntarily sign date inform consent , approve Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure . Exclusion Criteria 1 . History significant sensitivity allergy drug , include androgen , castor oil product excipients . 2 . Previous history current suspect prostate breast cancer , and/or previous history cancer ( except basal cell carcinoma skin ) . 3 . Subjects stable medication regimen least three month treatment chronic condition hypertension , hyperlipidemia diabetes mellitus . 4 . Use known inhibitor ( e.g. , ketoconazole ) inducer ( e.g. , dexamethasone , phenytoin , rifampin , carbamazepine ) cytochrome P450 3A ( CYP3A ) within 30 day prior study drug administration end study . 5 . Use drug within 5 halflives last dose past 6 month prior Study Day 2 without principal investigator and/or sponsor approval . 6 . Receipt drug injection within 30 day 10 halflives ( ever longer ) prior study drug administration without principal investigator and/or sponsor approval .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>dose escalate</keyword>
</DOC>